326 related articles for article (PubMed ID: 15899812)
1. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
[TBL] [Abstract][Full Text] [Related]
2. The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity.
Henderson CJ; Pass GJ; Wolf CR
Toxicol Lett; 2006 Mar; 162(1):111-7. PubMed ID: 16343823
[TBL] [Abstract][Full Text] [Related]
3. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
Huang Z; Raychowdhury MK; Waxman DJ
Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
[TBL] [Abstract][Full Text] [Related]
4. A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition.
Gu J; Chen CS; Wei Y; Fang C; Xie F; Kannan K; Yang W; Waxman DJ; Ding X
J Pharmacol Exp Ther; 2007 Apr; 321(1):9-17. PubMed ID: 17218484
[TBL] [Abstract][Full Text] [Related]
5. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
[TBL] [Abstract][Full Text] [Related]
6. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice.
Arlt VM; Stiborová M; Henderson CJ; Thiemann M; Frei E; Aimová D; Singh R; Gamboa da Costa G; Schmitz OJ; Farmer PB; Wolf CR; Phillips DH
Carcinogenesis; 2008 Mar; 29(3):656-65. PubMed ID: 18204078
[TBL] [Abstract][Full Text] [Related]
7. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
[TBL] [Abstract][Full Text] [Related]
8. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
[TBL] [Abstract][Full Text] [Related]
9. Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors.
Huang Z; Waxman DJ
Cancer Gene Ther; 2001 Jun; 8(6):450-8. PubMed ID: 11498765
[TBL] [Abstract][Full Text] [Related]
10. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.
Schwartz PS; Chen CS; Waxman DJ
Cancer Gene Ther; 2003 Aug; 10(8):571-82. PubMed ID: 12872138
[TBL] [Abstract][Full Text] [Related]
11. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Jounaidi Y; Hecht JE; Waxman DJ
Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
13. The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma.
Afsharian P; Möllgård L; Hassan Z; Xie H; Kimby E; Hassan M
Eur J Haematol; 2005 Sep; 75(3):206-11. PubMed ID: 16104876
[TBL] [Abstract][Full Text] [Related]
14. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
Chen CS; Jounaidi Y; Waxman DJ
Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
Chen L; Yu LJ; Waxman DJ
Cancer Res; 1997 Nov; 57(21):4830-7. PubMed ID: 9354446
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the hepatic CYP reductase null mouse model and its potential application in drug discovery.
Boggs JW; Hop CE; McNamara E; Deng Y; Messick K; West K; Choo EF
Mol Pharm; 2014 Mar; 11(3):1062-8. PubMed ID: 24450768
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the metabolism of midazolam in C57BL/6J and hepatic reductase null (HRN) mice.
Grimsley A; Foster A; Gallagher R; Hutchison M; Lundqvist A; Pickup K; Wilson ID; Samuelsson K
Biochem Pharmacol; 2014 Dec; 92(4):701-11. PubMed ID: 25450676
[TBL] [Abstract][Full Text] [Related]
18. Role of small intestinal cytochromes p450 in the bioavailability of oral nifedipine.
Zhang QY; Kaminsky LS; Dunbar D; Zhang J; Ding X
Drug Metab Dispos; 2007 Sep; 35(9):1617-23. PubMed ID: 17567730
[TBL] [Abstract][Full Text] [Related]
19. Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35.
Schwartz PS; Chen CS; Waxman DJ
Cancer Res; 2002 Dec; 62(23):6928-37. PubMed ID: 12460909
[TBL] [Abstract][Full Text] [Related]
20. Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity.
Xue X; Gong L; Qi X; Wu Y; Xing G; Yao J; Luan Y; Xiao Y; Li Y; Wu X; Chen M; Gu J; Ren J
Toxicol Lett; 2011 Aug; 205(1):47-54. PubMed ID: 21596114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
